Editorial introductions
Pourquoi ce travail est dans la base
Une base qui oublie comment elle a trouvé un travail ne peut pas être vérifiée. Voici les voies qui ont admis celui-ci.
Notice bibliographique
Résumé
Current Opinion in Oncology was launched in 1989. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of psychiatry is divided into 15 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Journal's Section Editors for this issue. SECTION EDITORS Giuseppe CuriglianoGiuseppe CuriglianoGiuseppe Curigliano, MD, PhD is Senior Deputy Director at the IEO, Division of Medical Oncology. He is a clinician and researcher specializing in breast cancer. Dr Curigliano earned his MD at the Universita’ Cattolica del Sacro Cuore, in Rome, Italy, and also holds a PhD in clinical pharmacology from the University of Pisa, Italy. He completed his fellowship in South Carolina Medical School, Charleston, USA; and Columbia University in New York City, USA. Dr Curigliano is an active member of ASCO and ESMO and a founding member of and scientific coordinator for the International Cardio-Oncology Society. He has been Visiting Professor at the Dana Farber Cancer Insititute, Harvard Medical School, USA and is a member of the Scientific Committee of the International Breast Cancer Study Group. He has a strong background in preclinical and phase I studies and he coordinates a research platform for new drug development in breast cancer. Dr Curigliano has published many papers and reviews for a number of prestigious oncology journals. Steven T. RosenSteven T. RosenSteven T. Rosen, MD, FACP, is Genevieve Teuton Professor of Medicine at the Feinberg School of Medicine, Northwestern University, USA, and Director of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and Director of Cancer Programs at Northwestern Memorial Hospital. Following his graduation with distinction from Northwestern University Medical School's Six-Year Honors Program in 1976, Dr Rosen completed his residency in Internal Medicine at Northwestern and a fellowship in Medical Oncology at the National Cancer Institute, USA. Dr Rosen's laboratory research focuses on experimental therapeutics and hematologic malignancies. Dr Rosen has received numerous grants awards and contracts and has published more than 200 scientific papers. As Director of the Cancer Center, Dr Rosen has successfully competed for an NCI Cancer Center Support Grant, NCI grants for his laboratory research, an NCI RAID Contract grant for the development of a novel purine analog, and grants from the Leukemia and Lymphoma Society of America and the American Cancer Society. Dr Rosen serves on several editorial boards and is editor of Cancer Treatment & Research and Oncology News International. He is a member of all major national associations that focus on oncology and has held leadership positions in the Eastern Cooperative Oncology Group, the American Association of Cancer Institutes and the National Comprehensive Cancer Network. He serves on the advisory boards of several NCI-designated Cancer Centers, the Leukemia and Lymphoma Society of America, the Multiple Myeloma Research Foundation, the Lymphoma Research Foundation and the Wendy Will Cancer Research Foundation. He has also served as an advisor to the UK's Cancer Research Campaign. Dr Rosen was the recipient of Northwestern University Medical School's Alumni Achievement Award (1994), the Martin Luther King Humanitarian Award from Northwestern Memorial Hospital (1995), the Marv Samuel Award from the Chicago Baseball Cancer Charities (1996) and recognition from the Women's Board of Northwestern Memorial Hospital for Compassionate Care (1996). He is acknowledged in Best Doctors and Oncologists in America, and Best Doctors in Chicago. Marc SansonMarc SansonMarc Sanson, MD, PhD is Professor at P&M Curie University, Department of Neurology and Neuro-oncology, Pitié-Salpêtrière Hospital, in Paris, France. Dr Sanson has published numerous research articles on neuro-oncology, including more than 100 papers dedicated to gliomas, as well as book chapters, and is a frequently requested lecturer on this topic. His main interest is focused on clinical and translational research on gliomas, including novel therapies, genetic alterations and new biomarkers. He is a reviewer on a number of journals, including the Journal of Clinical Oncology, Lancet, Annals of Neurology, Neurology, Cancer, Clinical Cancer Research, and Cancer Research. Dr Sanson earned his MD at University R Descartes and his PhD at University D Diderot, both in Paris, France. He completed a residency in Neurology in Paris, and a post-doc at McGill University, Canada. Miguel A. SanzMiguel A. SanzMiguel A. Sanz is Head at the Department of Hematology and Bone Marrow Transplant Unit at the University Hospital La Fe in Valencia, Spain, as well as Associate Professor of Medicine at the University of Valencia. After earning his medical degree at the University of Salamanca in Spain, he was intern, resident and subsequently completed a fellowship in Hematology at the University Hospital La Fe. Professor Sanz is Chairman of the Spanish PETHEMA Group and of the Working Parties of Acute Promyelocytic Leukemia, Acute Myeloid Leukemia and Infections in Neutropenic Patients. He is currently a reviewer for numerous high-profile medical journals, and has authored more than 400 papers, 80 book chapters, and in excess of 950 abstracts at national and international meetings.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Prédiction distillée sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.
Scores Codex et Gemma par catégorie
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,000 | 0,000 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,000 | 0,000 |
| Bibliométrie | 0,000 | 0,000 |
| Études des sciences et des technologies | 0,000 | 0,000 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,000 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,000 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,000 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découle